| May 31 |
Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
|
| May 31 |
Gilead's Trodelvy falls short in significantly improving overall survival in NSCLC
|
| May 31 |
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
|
| May 31 |
Gilead’s Trodelvy misses goal in bladder cancer study
|
| May 31 |
Gilead’s Phase III urothelial cancer trial fails to meet primary endpoint
|
| May 30 |
Gilead's Trodelvy misses primary endpoint in phase 3 bladder cancer trial
|
| May 30 |
Gilead Provides Update on Phase 3 TROPiCS-04 Study
|
| May 29 |
Buy Low, Hold Long: 2 Crushed Dividend Stocks To Buy For High Yields And Long-Term Gains
|
| May 29 |
Gilead and Cartography enter deal to develop cancer therapies
|
| May 28 |
Gilead Sciences: Seriously Undervalued At Peak Pessimism
|
